Kim Donghwa, Dan Han C, Park Sungman, Yang Lin, Liu Qiyuan, Kaneko Satoshi, Ning Jinying, He Lili, Yang Hua, Sun Mei, Nicosia Santo V, Cheng Jin Q
Department of Pathology, University of South Florida College of Medicine and H. Lee Moffitt Cancer Center, Tampa, Florida 33612, USA.
Front Biosci. 2005 Jan 1;10:975-87. doi: 10.2741/1592.
During the past decade, Akt (also known as protein kinase B, PKB) has been extensively studied. It regulates a variety of cellular processes by mediating extracellular (mitogenic growth factor, insulin and stress) and intracellular (altered tyrosine receptor kinases, Ras and Src) signals. Activation of Akt by these signals is via its pleckstrin homology (PH) domain binding to products of phosphatidylinositol 3-kinase (PI3K). This process is negatively regulated by a dual phosphatase PTEN tumor suppressor. Today, more than 30 Akt substrates have been identified. These phosphorylation events mediate the effects of Akt on cell survival, growth, differentiation, angiogenesis, migration and metabolism. Further, PI3K/PTEN/Akt pathway is frequently altered in many human malignancies and overexpression of Akt induces malignant transformation and chemoresistance. Thus, the Akt pathway is a major target for anti-cancer drug development. This review focuses on Akt signaling mechanism in oncogenesis and chemoresistance, and ongoing translational efforts to therapeutically target Akt.
在过去十年中,Akt(也称为蛋白激酶B,PKB)受到了广泛研究。它通过介导细胞外(促有丝分裂生长因子、胰岛素和应激)和细胞内(改变的酪氨酸受体激酶、Ras和Src)信号来调节多种细胞过程。这些信号对Akt的激活是通过其普列克底物蛋白同源(PH)结构域与磷脂酰肌醇3激酶(PI3K)的产物结合来实现的。这一过程受到双磷酸酶PTEN肿瘤抑制因子的负调控。如今,已鉴定出30多种Akt底物。这些磷酸化事件介导了Akt对细胞存活、生长、分化、血管生成、迁移和代谢的影响。此外,PI3K/PTEN/Akt通路在许多人类恶性肿瘤中经常发生改变,Akt的过表达会诱导恶性转化和化疗耐药性。因此,Akt通路是抗癌药物开发的主要靶点。本综述重点关注Akt在肿瘤发生和化疗耐药中的信号传导机制,以及针对Akt进行治疗的正在进行的转化研究工作。